CDP‐choline increases plasma ACTH and potentiates the stimulated release of GH, TSH and LH: the cholinergic involvement

  title={CDP‐choline increases plasma ACTH and potentiates the stimulated release of GH, TSH and LH: the cholinergic involvement},
  author={Sinan Çavun and Vahide Savci},
  journal={Fundamental \& Clinical Pharmacology},
  • S. ÇavunV. Savci
  • Published 1 October 2004
  • Biology, Medicine
  • Fundamental & Clinical Pharmacology
In the present study, we investigated the effect of intracerebroventricular (i.c.v.) administration of cytidine‐5′‐diphosphate (CDP) choline on plasma adrenocorticotropin (ACTH), serum growth hormone (GH), thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels in conscious rats. The involvement of cholinergic mechanisms in these effects was also determined. In basal conditions, CDP‐choline (0.5, 1.0 and 2.0 μmol, i.c.v.) increased plasma ACTH… 

Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations.

It is concluded that i.c.p. administration of CDP-choline or its cholinergic metabolites phosphocholine and choline increases plasma adrenaline and noradrenaline concentrations by enhancing nicotiniccholinergic neurotransmission in the sympatho-adrenal system.

The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models

Results indicate that CDP-choline-elicited antihyperalgesic effect in different models of pain occurs through mechanisms that seem to involve an interaction with supraspinal &agr;7-selective nicotinic ACh receptors, and &ggr;-aminobutyric acid B receptors, whereas central opioid receptors have a role only in the neuropathic pain model.

Involvement of the histaminergic system in cytidine 5'-diphosphocholine-induced reversal of critical haemorrhagic hypotension in rats.

The present results show that the central Histaminergic system, through the activation of H(1) histaminergic receptors, is involved in CDP-choline-induced resuscitating effect in haemorrhage-shocked rats.

Centrally injected CDP‐choline increases plasma vasopressin levels by central cholinergic activation

In conclusion, intracerebroventricularly injected CDP‐choline can increase plasma vasopressin levels by activating central nicotinic cholinergic receptors through the activation of presynaptic Cholinergic mechanisms.

Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level.

Atropine blockade of GHRH-induced GH secretion appears to be exerted at a site other than pituitary, and atropine blocked Ach-stimulating activity.

Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin.

The present results indicate that muscarinic cholinergic agonists and antagonists modulate GHRH-induced GH release in the rat and suggest that the effect of Cholinergic modulation takes place through SRIF.

Centrally administered choline increases plasma prolactin levels in conscious rats

Interaction between nicotinic cholinergic receptors and alpha-2 adrenergic systems in regulating growth hormone secretion in conscious rats.

It is suggested that central nicotinic receptors have a stimulatory role in regulating GH secretion and that the Nicotinic cholinergic system coupled with the alpha-2 adrenergic mechanism is involved in GH secretion induced by galanin in conscious rats.

Evidence for a cholinergic component in the neuroendocrine control of luteinizing hormone (LH) secretion.

The data indicate that from HFs incubated in vitro, Ach is able to release a factor which increases the secretion of LH from AP tissue and that this effect of Ach follows the general rules of cholinergic systems (blockade by atropine, potentiation by prostigmine, etc); and that the LH-RH releasing activity of Ach is not linked to the liberation of catecholamines.

Neuroendocrine control of growth hormone secretion

  • E. Müller
  • Biology, Medicine
    Naunyn-Schmiedeberg's Archives of Pharmacology
  • 2004
Better understanding of the function of GHRH, SS, and their receptors and, hence, of neural regulation of GH secretion in health and disease has been achieved with the discovery of a new class of fairly specific, orally active, small peptides and their congeners, the GH-releasing peptides, acting on specific, ubiquitous seven-transmembrane domain receptors, whose natural ligands are not yet known.

Acetylcholine and the release of the follicle-stimulating hormone-releasing factor.

Cetylcholine significantly enhances FSH release when added to the incubation media of flasks containing both AP tissue and HF, and atropine, an anticholinergic drug, has no effect on the release of FSH from APincubated alone.